Log In

New? Register Here

Idenix Pharmaceuticals Inc

4th Floor, 320 Bent Street
CAMBRIDGE, MA 02141-2025

  • Main Phone: (617) 995-9800
  • Fax Number: (617) 995-9801
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Endorsements: None Provided
  • Announcements: 0


Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. As of December 31, 2012, the Company's primary research and development focused on the treatment of patients with hepatitis C virus (HCV). In June 2012, the Company completed a three-day proof-of-concept study designed to evaluate 64 treatment-naive HCV genotype 1, 2, 3 or 4-infected patients. In July 2012, the FDA granted Fast Track designation for IDX719. The Company, as of December 31, 2012, was developing nucleotide polymerase inhibitors and NS 5A inhibitors to inhibits HCV replication, which include nucleoside/nucleotide polymerase inhibitors and NS5A Inhibitors. On January 25, 2013, the Company entered into a non-exclusive collaboration agreement with Janssen Pharmaceuticals, Inc for the clinical evaluation of all oral DAA HCV combination therapies.


Not provided at this time


Not provided at this time


There are no company announcements at this time.

Company's Strengths and Specialties

There is no information provided at this time.